Oxiracetam

Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidineacetamide; CAS 62613-82-5; molecular formula C6H10N2O3; molecular weight 158.16) is a hydroxylated piracetam analog developed by ISF (now Smith Kline Beecham) in Italy in the 1970s and marketed in Italy and several Eastern European countries under names including Neuractiv and Neuromet for cognitive impairment in elderly patients and post-traumatic memory disorders. The structural modification is a 4-hydroxy substitution on the pyrrolidinone ring, which increases polarity relative to piracetam and modestly improves blood-brain barrier penetration through specific membrane transporters rather than passive diffusion. The mechanism overlaps with piracetam (membrane fluidity, indirect cholinergic, AMPA modulation) but is reported to have somewhat stronger pro-cholinergic activity, attributed to enhanced high-affinity choline uptake into cortical synaptosomes. The clinical evidence base in mild cognitive impairment and Alzheimer disease is modest; randomized trials show small but reproducible improvements in attention and concentration measures, with effect sizes generally smaller than those reported for cholinesterase inhibitors. Pharmacokinetics: plasma half-life 8 to 10 hours; oral bioavailability essentially complete; the compound is renally excreted unchanged. The research literature reports dose ranges of approximately 800 to 2400 mg. The safety profile parallels piracetam; the compound has not produced serious adverse events at studied doses across decades of use in marketed jurisdictions.